XNAS · Healthcare · Drug Manufacturers - Specialty & Generic
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2025-11-05 | Q3 2025 | 0.13 | 0.21 | +61.54% | $94.9M | ✅ Beat | — | — | — |
| 2025-08-07 | Q2 2025 | 0.13 | 0.14 | +7.69% | $91.9M | ✅ Beat | +5.23% | -3.98% | -9.04% |
| 2025-02-20 |
| Q4 2024 |
| 0.04 |
| 0.05 |
| +25.00% |
| $72.0M |
| ✅ Beat |
| +0.00% |
| +1.88% |
| +3.83% |
| 2024-11-07 | Q3 2024 | 0.11 | 0.12 | +9.09% | $80.6M | ✅ Beat | +8.24% | +11.40% | +6.82% |
| 2024-08-06 | Q2 2024 | 0.06 | 0.08 | +33.33% | $73.8M | ✅ Beat | +6.97% | +9.85% | +7.96% |
| 2024-05-08 | Q1 2024 | -0.02 | -0.07 | -250.00% | $50.8M | ❌ Miss | -5.49% | -5.24% | +3.52% |
| 2024-02-22 | Q4 2023 | -0.01 | 0.00 | +100.00% | $55.6M | ✅ Beat | — | — | — |
| 2023-11-02 | Q3 2023 | -0.01 | 0.10 | +1100.00% | $69.5M | ✅ Beat | +1.07% | -6.97% | -1.07% |
Showing last 8 quarters.